Figures & data
Figure 1. Functional imaging at different treatment time points. [F-18]2-deoxy-2-fluoro-d-glucose positron emission tomography (F-18-FDG PET/CT) maximum intensity projection images (antero-posterior view) demonstrating the FDG uptake during the treatment course of the patient. Upon inclusion (A) high accumulation of FDG was shown within the target lesion in the liver. Quantitative evaluation of FDG uptake of the first follow-up scan after three weeks of lenalidomide monotherapy (B) revealed a reduction of the maximum standard uptake value (SUVmax) within the target lesion by 45%, from initially 12.1 to 6.7. Restaging after three weeks of combined lenalidomide and cetuximab treatment showed a slight increase of the SUVmax to 7.6.
![Figure 1. Functional imaging at different treatment time points. [F-18]2-deoxy-2-fluoro-d-glucose positron emission tomography (F-18-FDG PET/CT) maximum intensity projection images (antero-posterior view) demonstrating the FDG uptake during the treatment course of the patient. Upon inclusion (A) high accumulation of FDG was shown within the target lesion in the liver. Quantitative evaluation of FDG uptake of the first follow-up scan after three weeks of lenalidomide monotherapy (B) revealed a reduction of the maximum standard uptake value (SUVmax) within the target lesion by 45%, from initially 12.1 to 6.7. Restaging after three weeks of combined lenalidomide and cetuximab treatment showed a slight increase of the SUVmax to 7.6.](/cms/asset/29e41f20-a8cc-4dc9-b347-f8f30b6751b4/kcbt_a_10927327_f0001.gif)
Figure 2. Chromium-release measurement of ADCC of patient blood samples at different treatment time points. Time- and treatment-dependent enhancement of specific tumor cell lysis mediated by patient-derived NK cells toward naive or cetuximab-coated SCC25 cells (ADCC) (effector [NK]: target [SCC25] cell ratio 20:1 or 40:1). Specific lysis was calculated from radioactive chrome release assay. Data represent mean percent of lysis ± SD of triplicates.
![Figure 2. Chromium-release measurement of ADCC of patient blood samples at different treatment time points. Time- and treatment-dependent enhancement of specific tumor cell lysis mediated by patient-derived NK cells toward naive or cetuximab-coated SCC25 cells (ADCC) (effector [NK]: target [SCC25] cell ratio 20:1 or 40:1). Specific lysis was calculated from radioactive chrome release assay. Data represent mean percent of lysis ± SD of triplicates.](/cms/asset/48280aac-1490-4e4c-a592-815461d2b489/kcbt_a_10927327_f0002.gif)